MX2021012892A - Composiciones y metodos para potenciar derivados de 4-aminofenoles. - Google Patents

Composiciones y metodos para potenciar derivados de 4-aminofenoles.

Info

Publication number
MX2021012892A
MX2021012892A MX2021012892A MX2021012892A MX2021012892A MX 2021012892 A MX2021012892 A MX 2021012892A MX 2021012892 A MX2021012892 A MX 2021012892A MX 2021012892 A MX2021012892 A MX 2021012892A MX 2021012892 A MX2021012892 A MX 2021012892A
Authority
MX
Mexico
Prior art keywords
methods
aminophenols
derivatives
potentiating
compositions
Prior art date
Application number
MX2021012892A
Other languages
English (en)
Inventor
Ascher Shmulewitz
Adi Zuloff-Shani
Ephraim Brener
Original Assignee
Scisparc Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scisparc Ltd filed Critical Scisparc Ltd
Publication of MX2021012892A publication Critical patent/MX2021012892A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente descripción proporciona composiciones farmacéuticas y métodos para tratar condiciones susceptibles al paracetamol, como el dolor y fiebre. Las composiciones farmacéuticas comprenden ciertas combinaciones de derivados de 4-Aminofenoles y N-aciletanolaminas. También se describen métodos y equipos para tratar o minimizar condiciones susceptibles al paracetamol.
MX2021012892A 2019-04-23 2020-04-22 Composiciones y metodos para potenciar derivados de 4-aminofenoles. MX2021012892A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962837274P 2019-04-23 2019-04-23
PCT/IB2020/000317 WO2020217100A1 (en) 2019-04-23 2020-04-22 Compositions and methods for potentiating derivatives of 4-aminophenols

Publications (1)

Publication Number Publication Date
MX2021012892A true MX2021012892A (es) 2021-11-17

Family

ID=72941597

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012892A MX2021012892A (es) 2019-04-23 2020-04-22 Composiciones y metodos para potenciar derivados de 4-aminofenoles.

Country Status (9)

Country Link
US (1) US20220211647A1 (es)
EP (1) EP3958850A4 (es)
JP (1) JP2022530207A (es)
CN (1) CN113747888A (es)
AU (1) AU2020263152A1 (es)
CA (1) CA3134885A1 (es)
IL (1) IL287410A (es)
MX (1) MX2021012892A (es)
WO (1) WO2020217100A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3288553T3 (da) * 2015-04-29 2023-01-23 Scisparc Ltd Kombinationer af cannabinoider og n-acylethanolaminer
ES2580508B1 (es) * 2016-04-11 2018-09-12 Servicio Andaluz De Salud Composiciones para la prevención y/o tratamiento de los trastornos por uso de alcohol.

Also Published As

Publication number Publication date
AU2020263152A1 (en) 2021-10-21
CA3134885A1 (en) 2020-10-29
CN113747888A (zh) 2021-12-03
EP3958850A4 (en) 2023-04-26
IL287410A (en) 2021-12-01
EP3958850A1 (en) 2022-03-02
WO2020217100A1 (en) 2020-10-29
JP2022530207A (ja) 2022-06-28
US20220211647A1 (en) 2022-07-07

Similar Documents

Publication Publication Date Title
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
CR20200614A (es) Compuestos heterocíclicos como inmunomoduladores
MX2021009259A (es) Conjugados de il-2 y metodos de uso del mismo.
JOP20220087A1 (ar) أمينات ثنائية الحلقة كمثبطات لـ cdk2
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
MX2021009246A (es) Inmunomoduladores, composiciones y metodos de los mismos.
MY197635A (en) Benzooxazole derivatives as immunomodulators
WO2018234793A3 (en) Antibodies
JOP20200152A1 (ar) مركبات حلقية كبرى لعلاج مرض
WO2020102646A3 (en) Inhibitors of arg1 and/or arg2
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
MX2022002740A (es) Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
MX2021002916A (es) Pirfenidona enriquecida con deuterio y métodos para su uso.
MX2022001004A (es) Inhibidores de enzimas.
MX2021001471A (es) Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
MX2019001608A (es) Tratamiento de tumores y linfomas no de hodgkin solidos, reincididos y/o refractarios.
MX2022009762A (es) Moduladores del purinorreceptor 3 p2x (p2x3).
MX2021013602A (es) Inhibidores de jak.
MX2022000712A (es) Moduladores de nlrp3.
ZA202106519B (en) Caspase inhibitors and methods of use thereof
WO2021041324A3 (en) Compositions and methods for the treatment of pathological pain and itch
MX2021008941A (es) Moduladores gpr35.